Combination lysine acetylsalicylate - clopidogrel — Competitive Intelligence Brief

Combination lysine acetylsalicylate - clopidogrel (Combination lysine acetylsalicylate - clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combination. Area: Cardiovascular.

phase 3 Antiplatelet agent combination Cyclooxygenase-1 (COX-1) and P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Combination lysine acetylsalicylate - clopidogrel (Combination lysine acetylsalicylate - clopidogrel) — University Hospital, Bordeaux. This combination inhibits platelet aggregation through two complementary pathways: lysine acetylsalicylate irreversibly blocks thromboxane A2 synthesis, while clopidogrel inhibits ADP-mediated platelet activation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combination lysine acetylsalicylate - clopidogrel TARGET	Combination lysine acetylsalicylate - clopidogrel	University Hospital, Bordeaux	phase 3	Antiplatelet agent combination	Cyclooxygenase-1 (COX-1) and P2Y12 receptor
Dual antithrombotc therapy-1	Dual antithrombotc therapy-1	The First Affiliated Hospital with Nanjing Medical University	marketed	Antiplatelet agent combination
Ticagrelor plus aspirin	Ticagrelor plus aspirin	Fujian Medical University	marketed	Dual antiplatelet agent combination	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Dual antiplatelet agent duration	Dual antiplatelet agent duration	Seoul National University Hospital	marketed	Antiplatelet agent combination	Cyclooxygenase (COX) and P2Y12 receptor
Dabigatran + Ticagrelor	Dabigatran + Ticagrelor	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combination class)

1. Beijing Tiantan Hospital · 1 drug in this class
2. Biosensors Europe SA · 1 drug in this class
3. Inova Health Care Services · 1 drug in this class
4. Kyunghee University Medical Center · 1 drug in this class
5. Seoul National University Hospital · 1 drug in this class
6. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
7. University Hospital, Bordeaux · 1 drug in this class